TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose A telomerase reverse transcriptase (TERT) promoter mutation was identified in thyroid cancer. This TERT promoter mutation is thought to be a prognostic molecular marker, because its association with tumor aggressiveness, persistence/recurrence, and disease-specific mortality in papillary thyroid carcinoma (PTC) has been reported. In this study, we attempted to determine whether the impact of the TERT promoter mutation on PTC persistence/ recurrence is independent of clinicopathological parameters. Materials and Methods Using propensity score matching, 39 patients with PTC persistence or recurrence were matched with 35 patients without persistence or recurrence, with a similar age, sex, tumor size, multifocality, bilaterality, extrathyroidal extension, and lymph node metastasis. The TERT promoter and the BRAF V600E mutations were identified from PTC samples. Results The TERT promoter mutation was detected in 18% of PTC patients (13/74). No significant difference in the frequency of the TERT promoter mutation was observed between the persistence/ recurrence group and the non-recurrence group. Conclusion These results suggest that the prognostic implications of the TERT promoter mutation are dependent on clinicopathological parameters.
Abstract
Purpose A telomerase reverse transcriptase (TERT) promoter mutation was identified in thyroid cancer. This TERT promoter mutation is thought to be a prognostic molecular marker, because its association with tumor aggressiveness, persistence/recurrence, and disease-specific mortality in papillary thyroid carcinoma (PTC) has been reported. In this study, we attempted to determine whether the impact of the TERT promoter mutation on PTC persistence/ recurrence is independent of clinicopathological parameters. Materials and Methods Using propensity score matching, 39 patients with PTC persistence or recurrence were matched with 35 patients without persistence or recurrence, with a similar age, sex, tumor size, multifocality, bilaterality, extrathyroidal extension, and lymph node metastasis. The TERT promoter and the BRAF V600E mutations were identified from PTC samples. Results The TERT promoter mutation was detected in 18% of PTC patients (13/74). No significant difference in the frequency of the TERT promoter mutation was observed between the persistence/ recurrence group and the non-recurrence group. Conclusion These results suggest that the prognostic implications of the TERT promoter mutation are dependent on clinicopathological parameters.
참고문헌 (21)
- Smekalova EM, "Telomerase RNA biosynthesis and processing", Biochemistry(Mosc), 77, pp.1120~1128 (2012)
- Kim NW, "Specific association of human telomerase activity with immortal cells and cancer", Science, 266, pp.2011~2015 (1994)
- Clark GM, "Telomerase activity and survival of patients with node-positive breast cancer", J Natl Cancer Inst, 89, pp.1874~1881 (1997)
- Huang FW, "Highly recurrent TERT promoter mutations in human melanoma", Science, 339, pp.957~959 (2013)
- Soares P, "Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas", Curr Genomics, 12, pp.609~617 (2011)
- Matthews P, "Telomerase activity and telomere length in thyroid neoplasia : biological and clinical implications", J Pathol, 194, pp.183~193 (2001)
- Capezzone M, "Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancer", J Clin Endocrinol Metab, 96, pp.1852~1856 (2011)
- Liu X, "Highly prevalent TERT promoter mutations in aggressive thyroid cancers", Endocr Relat Cancer, 20, pp.603~610 (2013)
- Landa I, "Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease", J Clin Endocrinol Metab, 98, pp.1562~1566 (2013)
- Liu X, "TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer", J Clin Endocrinol Metab, 99, pp.1130~1136 (2014)
- Melo M, "TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas", J Clin Endocrinol Metab, 99, pp.754~765 (2014)
- Liu T, "The age-and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas", Oncogene, 33, pp.4978~4984 (2014)
- Xing M, "BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence", J Clin Oncol, 32, pp.2718~2726 (2014)
- Xing M, "Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer", JAMA, 309, pp.1493~1501 (2013)
- Xing M, "Association between BRAF V600E mutation and recurrence of papillary thyroid cancer", J Clin Oncol, 33, pp.42~50 (2015)
- Blasco MA, "Telomere length, stem cells and aging", Nat Chem Biol, 3, pp.640~649 (2007)
- Canela A, "High-throughput telomere length quantification by FISH and its application to human population studies", Proc Natl Acad Sci U S A, 104, pp.5300~5305 (2007)
- de Biase D, "TERT promoter mutations in papillary thyroid microcarcinomas", Thyroid, 25, pp.1013~1019 (2015)
- Xing M, "BRAF mutation in thyroid cancer", Endocr Relat Cancer, 12, pp.245~262 (2005)
- Xing M, "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer", J Clin Endocrinol Metab, 90, pp.6373~6379 (2005)
- Kim TH, "The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis", Cancer, 118, pp.1764~1773 (2012)